Classification of Pathogenic Bacteria in Cerebrospinal Fluid of Patients with Intracranial Infection After Neurosurgery and Selective Use of Antibacterial Agents

Yunxiang Chen,1 Zhengyang Li,2 Jihong Liu,1 Yuejun Fan,1 Minfeng Tong,1 Jianglong Lu,3 and Gezhi Zhou1, *

1Department of Neurosurgery, Jinhua City Central Hospital, Jinhua 321000, Zhejiang Province, China
2Department of Neurosurgery, the Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou 310009, Zhejiang Province, China
3Department of Neurosurgery, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325000, Zhejiang Province, China
*
Corresponding author: Gezhi Zhou, Department of Neurosurgery, Jinhua City Central Hospital, Jinhua 321000, Zhejiang Province, China. Tel: +86-57982553273, E-mail: zhougezhijcch@sina.com

Received 2017 August 23; Revised 2018 January 17; Accepted 2018 January 29.

Abstract

Background: Anti-infective treatment has become troublesome owing to aggravated resistance to antibacterial agents. 
Objectives: This study aimed at investigating the distribution characteristics and drug resistance changes of pathogenic bacteria in cerebrospinal fluid (CSF) of patients with intracranial infection receiving neurosurgery, and to provide evidence for rational use of antibacterial agents. 
Methods: Bacteria were collected from CSF cultures of all patients receiving neurosurgery in the hospital of the current research, from January 2013 to December 2015, and the same types of strains cultured from each case during the same infection were combined. A hospital information system (HIS) was then used to analyze the data of 120 patients, who received neurosurgery from January 2015 to June 2016 and had positive CSF bacterial culture results after surgery, and to treat them by rationally selecting antibacterial agents. 
Results: A total of 845 pathogenic bacterial strains were isolated from the CSF samples and cultured, of which 629 were gram-negative bacteria, accounting for 74.4%. Particularly, Acinetobacter baumannii had severe pan-resistance. There were 216 gram-positive bacteria, which accounted for 25.6% of all strains, and were mainly methicillin-resistant staphylococci, being basically resistant to penicillins and only susceptible to vancomycin and linezolid. After rational selection of antibacterial agents using HIS, based on the retrospective analysis results, 101 of the 120 patients were cured by vancomycin and linezolid (cure rate: 84.17%). 
Conclusions: Since the treatment outcomes after rational selection of antibacterial agents (i.e. vancomycin and linezolid) using HIS were satisfactory, the findings of retrospective analysis are of high clinical value. 
Keywords: Neurosurgery, Intracranial Infection, Cerebrospinal Fluid, Pathogenic Bacteria, Antibacterial Agents

1. Background

Neurosurgery has mainly been used to treat cerebral hemorrhage diseases, brain tumors, and traumatic brain injury. Patients mostly have critical illness, various degrees of disturbance of consciousness, long surgical time, high surgical difficulty, etc., thus they are prone to infection. Intracranial infection after neurosurgery is amongst serious complications, with incidence rates of 1.52% to 6.6% (1, 2). It is mainly manifested as meningitis, cerebritis, brain abscess, etc. (3). The pathogens for intracranial infection may be bacteria, viruses, parasites, mycoplasma, chlamydia, mold, and rickettsia (4). Mostly caused by trauma, surgery, blood-borne abscesses, parasitic diseases, granulomas and tuberculosis (5), intracranial infection commonly occurs within 3 to 7 days after surgery (6).

By evaluating the effects of intraventricularly administered vancomycin, Chen et al. reported that intracranial infections after craniotomy were mostly induced by methicillin-resistant staphylococci (7). Recently, Fang et al. reported an intraventricular tigecycline therapy for intracranial infection with extremely drug resistant Acinetobacter baumannii, which was rather problematic because of multidrug resistance and difficult penetration through the blood-brain barrier (8).

The drug resistance of pathogenic bacteria, especially Staphylococcus aureus, is increasing annually, also hindering effective clinical treatment (9). In the presence of the blood-brain barrier, high-dose anti-infective drugs are re-
quired to treat intracranial infection for a long time. As a result, anti-infective treatment has become troublesome owing to aggravated resistance to antibacterial agents (10).

2. Objectives

Thereby, motivated to explore the distribution of pathogenic bacteria upon intracranial infection after neurosurgery and considering changes of resistance to antibacterial agents, the CSF bacterial cultures from infected patients from January 2013 to December 2015 were retrospectively analyzed. Based on the results, similar cases from January 2015 to June 2016 were effectively treated by rationally selecting antibacterial agents.

3. Methods

3.1. Ethics Statement

This study was approved by the ethics committee of the study hospital (code number: JCCH-20130105), and written consent was obtained from all patients.

3.2. Clinical Data for Bacterial Classification

Bacteria were collected from CSF cultures of all patients receiving neurosurgery at the department of neurosurgery, Jinhua hospital, between January 2013 and December 2015, and the same kinds of strains cultured from each case during the same infection were combined. The CSF samples were mainly collected from patients diagnosed with intracranial tumors, cerebral hemorrhage, cerebral vascular malformations, subarachnoid hemorrhage, and intra-spinal tumors.

3.3. Clinical Data for Selection of Antibacterial Agents

A total of 120 patients, who received neurosurgery at the hospital of this study, between January 2015 and June 2016, were selected, including 63 males and 57 females aged between 10 and 75 years old (49.32 ± 4.21). There were 26 cases of cerebrovascular disease, 17 cases of traumatic brain injury, 38 cases of intracranial tumor, 22 cases of spinal cord lesion, and 17 cases of hydrocephalus. All patients had fever symptoms, with body temperatures of 38°C to 40.5°C. After having intracranial infection, their consciousness was gradually weakened, and 9 patients had severe disturbance of consciousness, accompanied by symptoms, such as vomiting and headache.

Inclusion criteria was having intracranial infection (including meningitis, ventriculitis, brain abscess, as well as subdural and epidural abscess) after surgery. Exclusion criteria were as follows: 1, diagnosis of brain abscess and other infectious diseases before surgery; 2, diagnosis of brain abscess or inflammation after surgery; 3, death or discharged for various reasons within 2 days after surgery.

3.4. Diagnostic Criteria for Intracranial Infection

Patients were diagnosed with intracranial infection if they did not have fever, aggravated headache, vomiting, disturbance of consciousness or neck stiffness for other reasons after surgery, and diagnosis was confirmed according to the diagnostic criteria for hospital-acquired meningitis in the United States (11). At present, the diagnostic criteria for intracranial bacterial infection were as follows: symptoms and signs of high fever, headache, vomiting, and neck stiffness in clinical practice. The results of CSF bacterial culture and Gram staining are the gold standards for diagnosing intracranial infection, including white blood cell count of 1000 to 10000/µL, glucose level < 40 mg/dL (2.5 mmol/L), protein level > 50 mg/dL, and lactate level > 3.5 mmol/L in CSF.

3.5. Distribution Characteristics of CSF Bacteria and Selection of Antibacterial Agents

The hospital information system (HIS) was used to search and analyze the data of patients, who received neurosurgery at the hospital of the current research, from January 2015 to June 2016, and had positive CSF bacterial culture results after surgery, mainly including name, age, diagnosis, pathogenic bacteria, susceptible drugs, and resistant and intermediate drugs.

3.6. Sample Collection

The 120 patients underwent lumbar puncture to take CSF for routine, biochemical, and bacterial culture examinations on the day when intracranial infection was found.

3.7. Treatment of CSF Samples

Turbid or purulent CSF was directly smeared on a glass slide, stained and examined by microscopy. Colorless transparent CSF was centrifuged to collect the precipitate that was then smeared on a glass slide and subjected to Gram staining. The infected bacteria were preliminarily classified according to staining results and morphological characteristics.

3.8. API Bacterial Identification

A single bacterial colony was isolated and prepared into a suspension. Next, 5 mL of sterile water was added in to a culture box, into which strips were placed. Meanwhile, the bacterial suspension was inoculated in small reaction tubes. Afterwards, designated wells were covered by paraffin oil, and the culture box was closed. The strips were thereafter placed in a 37°C incubator for 18 hours. According to the kit’s instructions (bioMerieux, France), reagents were added to appropriate wells. The results were recorded and analyzed by the Apilab software (France).
Table 1. Gram-Negative Bacteria in Cerebrospinal Fluid Cultures from 2013 to 2015 (n (%) )

| Type                        | 2013    | 2014    | 2015    |
|-----------------------------|---------|---------|---------|
| Total                       | 144 (68.9) | 270 (75.0) | 215 (77.9) |
| *Escherichia coli*          | 9 (4.3) | 23 (6.4) | 28 (10.3) |
| *Pseudomonas aeruginosa*    | 22 (10.5) | 45 (12.5) | 22 (9.8) |
| *Klebsiella pneumoniae*     | 19 (9.1) | 36 (10.0) | 32 (11.6) |
| *Acinetobacter baumannii*   | 42 (20.1) | 98 (27.2) | 69 (25.0) |
| *Acinetobacter lwoffii*     | 16 (7.7) | 56 (20.7) | 11 (4.0) |
| Other Gram-negative bacteria | 21 (10.0) | 30 (8.3) | 18 (6.5) |

Table 2. Gram-Positive Bacteria in Cerebrospinal Fluid Cultures from 2013 to 2015 (n (%) )

| Type                        | 2013    | 2014    | 2015    |
|-----------------------------|---------|---------|---------|
| Total                       | 65 (31.1) | 90 (25.0) | 61 (22.1) |
| *Streptococci*              | 1 (0.5) | 8 (2.2) | 3 (1.1) |
| *Staphylococcus aureus*     | 5 (2.4) | 4 (1.4) | 4 (1.4) |
| *Staphylococcus hominis*    | 7 (3.3) | 18 (5.0) | 14 (5.1) |
| *Enterococci*               | 11 (5.3) | 15 (4.2) | 6 (2.2) |
| *Staphylococcus epidermidis*| 20 (9.9) | 22 (6.3) | 13 (4.7) |
| Other staphylococci         | 21 (10.0) | 23 (6.4) | 21 (7.6) |
| *Staphylococcus auricularis*| 15 (7.2) | -       | -       |
| *Staphylococcus haemolyticus* | -     | 21 (5.8) | 20 (7.2) |
| *Staphylococcus capitis*    | -       | 29 (8.1) | 15 (5.4) |

Table 3. Pathogenic Bacteria (Number of Strains) Ranking Top Ten from 2013 to 2015

| Year | 2013          | 2014          | 2015          |
|------|---------------|---------------|---------------|
| Pathogenic bacteria (number of strains) | Acinetobacter baumannii (42) | Acinetobacter baumannii (98) | Acinetobacter baumannii (69) |
|      | *Pseudomonas aeruginosa* (22) | Acinetobacter baumannii (56) | Klebsiella pneumoniae (12) |
|      | *Staphylococcus epidermidis* (20) | *Pseudomonas aeruginosa* (45) | *Escherichia coli* (28) |
|      | Klebsiella pneumoniae (19) | Klebsiella pneumoniae (36) | Pseudomonas aeruginosa (22) |
|      | Acinetobacter baumannii (16) | Staphylococcus capitis (29) | Staphylococcus haemolyticus (20) |
|      | Staphylococcus auricularis (15) | *Escherichia coli* (23) | Staphylococcus capitis (15) |
|      | *Enterococci* (11) | *Staphylococcus epidermidis* (22) | Staphylococcus hominis (14) |
|      | *Escherichia coli* (9) | Staphylococcus haemolyticus (21) | Staphylococcus epidermidis (13) |
|      | Staphylococcus hominis (7) | Staphylococcus hominis (18) | Acinetobacter baumannii (11) |
|      | *Enterococci* (5) | *Enterococci* (15) | *Enterococci* (6) |

3.9. Bacterial Analysis and Identification

Pathogenic bacteria isolated from the CSF samples mentioned above were classified using the VITEK-60 analyzer and corresponding identification cards. The identified pathogenic bacterial strains were subjected to susceptibility tests with commonly used antibacterial agents in clinical practice, using the K-B method. The susceptibility cards were all purchased from Bio-Merieux (France). The test results were determined referring to the national committee for clinical laboratory standards (USA).
quality control strains were *Escherichia coli* (ATCC 25922), *Pseudomonas aeruginosa* (ATCC 27853), and *S. aureus* (ATCC 25923). All the above strains were provided by the national center for medical culture collections (China).

### 3.10. Treatment Methods

According to the results of bacterial culture, the patients were treated by proper antibiotics with the following methods: 1. Before the bacterial culture results were obtained, the patients were treated with blood-brain barrier-penetrating drugs, such as chloramphenicol and panipenem; 2. after the bacterial culture results were acquired, appropriate antibiotics were selected; 3. appropriate methods of administration were selected according to the state of patients. The patients with elevated CSF cell counts were intravenously injected with antibiotics. The patients with barely increased intracranial pressures were treated by intravenous and intrathecal injections. The patients with severe bacterial infection were treated by intravenous and intrathecal injections. Meanwhile, lumbar catheterization was employed for drainage; 4. vancomycin or ceftriaxone sodium was selected when the patients were treated by intrathecal administration; 5. during treatment, attention was paid to maintaining the electrolyte and pH balance.

### 3.11. Criteria for Therapeutic Effects

**Cured:** 1. Body temperature was within the normal range for 3 consecutive days; 2. the results of CSF bacterial culture were negative; 3. the white blood cell count was less than $8 \times 10^6 /L$; 4) there was no meningeal irritation sign.

## 4. Results

### 4.1. Distribution Characteristics of Bacteria in CSF

A total of 845 pathogenic bacterial strains (209 in 2013, 360 in 2014 and 276 in 2015) were isolated from CSF samples and cultured, of which 629 were gram-negative bacteria, accounting for 74.4%. The gram-negative bacteria were mainly *Acinetobacter baumannii*, *Klebsiella pneumoniae*, *Pseudomonas aeruginosa*, *Acinetobacter lwoffii*, and *Escherichia coli*. Particularly, the *A. baumannii* strains were ranked first each year (Table 1). On the other hand, there were 216 gram-positive bacteria, which accounted for 25.6% and were mainly *S. epidermidis*, *S. hominis*, and *S. aureus* (Table 2). Notably, *S. epidermidis* was the most common from 2013 to 2015. The types of pathogenic bacteria ranked as the top 10 did not change during 3 years (Table 3).

### 4.2. Susceptibility of Gram-Negative Bacteria in CSF to Common Antibacterial Agents

In 2013 and 2014, the susceptibility rates of *A. baumannii* toward all tested drugs were lower than 40%. From 2013...
4.3. Susceptibility of Gram-Positive Bacteria in CSF to Common Antibacterial Agents

Gram positive bacteria were mostly methicillin-resistant staphylococci. For example, > 90% of S. epidermidis (Figure 2A), S. aureus (Figure 2B), and S. hominis (Figure 2C) strains produced β-lactamase. Therefore, they were resistant to β-lactams, such as ampicillin, penicillin, oxacillin, and amoxicillin/clavulanic acid. They were only sensitive to vancomycin, linezolid, streptogramin, and rifampicin.

4.4. Selection of Antibacterial Agents

Based on the above results, HIS was used to search and analyze the data of 120 patients, who received neurosurgery at the hospital of the current research from January 2015 to June 2016, and had positive CSF bacterial culture results after surgery. The distribution of pathogenic bacteria was consistent with that mentioned above. After treatment based on the susceptibility rates of pathogenic bacteria compared with those in 2014 for the tested antibacterial agents, 101 patients were cured by vancomycin and linezolid (cure rate: 84.17%).

5. Discussion

At present, there is an increasing threat worldwide by drug-resistant bacteria. A report of the national nosocomial infections surveillance in 2004 showed that at intensive care units (ICU), patients with methicillin-resistant Staphylococcus aureus (MRSA) accounted for 63.3% of all cases infected by S. aureus (12). Currently, the incidence rates of intracranial infection after neurosurgery range from 1% to 10% (13). Especially, the patients receiving second surgery due to long-term ventricular drainage for subcutaneous effusion, after surgery for cerebrospinal fluid leaks and postoperative emergencies, are more prone to intracranial infection (14). The isolation rate of MRSA was, as revealed by a Chinese report, 69.5% among all S. aureus infections. The mortality rate of MRSA was 20 folds that of methicillin-sensitive S. aureus (15). Therefore, it is crucial to select proper antibacterial agents at first in the treatment of MRSA infections. As a glycopeptide, vancomycin is always given priority in treating MRSA, yet its minimal inhibitory concentration has been increasing annually due to the emergence of vancomycin-resistant MRSA (VRSA) (16).
to elevated dosage and frequency as well as appearance of vancomycin-resistant S. aureus and enterococci, thus the treatment outcomes of intracranial infection remains unsatisfactory.

Although over 3000 cases of CSF samples were subjected to bacterial culture and examination each year in the hospital of the current research, the proportion of positive cultures was < 10%, probably because long-term prophylactic use of antibacterial agents inhibited bacterial growth and gave inaccurate results. Thus, intracranial infection has often been treated empirically. To solve this problem, this research herein isolated 845 pathogenic bacterial strains from CSF samples for retrospective analysis, of which 629 were gram-negative bacteria, mainly being A. baumannii, K. pneumoniae, P. aeruginosa, A. lwofii and E. coli. The isolation rate of bacteria from the genus Acinetobacter (mainly A. baumannii) ranked first among those of all gram-negative bacteria, which may be associated with subsequent ICU treatment for critical cases after surgery. Besides, A. baumannii had severe multidrug resistance, which was only susceptible to polymyxin in 2015 with a rate of 87%.

Moreover, the susceptibility rates of A. baumannii towards each tested drug increased annually, which could mainly be ascribed to the following reasons. First, imipenem was seldom prescribed by neurosurgeons because of adverse reactions, such as epilepsy. Second, amikacin, gentamicin, and ciprofloxacin were not used at the hospital from 2013 to 2015. Third, patients had low tolerance to piperacillin and tazobactam, thus they were barely used. Recently, outbreaks of infections induced by pan-resistant A. baumannii, including ventilator-associated pneumonia, skin and soft tissue infections, urinary tract infection, secondary meningitis and bloodstream infection, have been witnessed worldwide (16). In contrast, related intracranial infection has seldom been reported. Nevertheless, once this infection occurs, only polymyxin and sulfonamide injections, which cannot be easily purchased, are suitable for treatment. Thus, it is necessary to establish an effective bacterial drug resistance monitory system based on the cooperation between the microorganism, nosocomial infection, and clinical departments in hospitals (17).

In this study, the number of K. pneumoniae strains increased from 9 to 14 in during 3 years. Though it was susceptible to imipenem and amikacin, the susceptibility rates decreased annually. Furthermore, since cephalosporins (e.g. cefuroxime and ceftriaxone) have been widely used for the prophylaxis of neurosurgery, gram-negative bacteria have become more resistant to 3rd generation cephalosporins and new β-lactams (18). Of all cephalosporins, cefepime had a high susceptibility rate. In 2013 and 2015, the susceptibility rates of P. aeruginosa was 69% and 70% respectively, yet that of Acinetobacter bacteria, K. pneumoniae, and E. coli was lower than 50% in 2015.

On the other hand, 216 gram-positive bacteria (25.6%) were cultured from 2013 to 2015, which were mainly β-lactamase-positive, and methicillin-resistant staphylococci. Only vancomycin, linezolid, and rifampicin worked for this group. However, the susceptibility rates of vancomycin and linezolid was reduced annually after being widely used. Hence, it is of great significance to effectively prevent further progression of vancomycin resistance in the treatment of postoperative intracranial infection. Staphylococci-induced meningitis can be well treated by linezolid and daptomycin (19, 20), and 70% of the former can penetrate the blood-brain barrier. Linezolid has not been approved by the US FDA to treat intracranial infection hitherto, yet it has definite therapeutic effects on that induced by vancomycin-resistant staphylococci and enterococci in clinical practice (21).

Finally, 120 eligible patients from 2015 to 2016 were treated based on retrospective results and HIS, instead of empirical use of antibacterial agents. After treatment based on the susceptibility rates of pathogenic bacteria to the tested antibacterial agents, 101 patients were cured by vancomycin and linezolid (cure rate: 84.17%), suggesting that the findings of retrospective analysis were of high clinical value.

5.1. Conclusion

In summary, this study retrospectively analyzed the distribution characteristics and drug resistance changes of pathogenic bacteria in CSF from patients with intracranial infection receiving neurosurgery, based on which antibacterial agents were rationenally selected for treating subsequently enrolled cases. Since the treatment outcomes after rational selection of antibacterial agents (i.e. vancomycin and linezolid) were satisfactory, the findings of retrospective analysis are valuable, paving the way for further studies in clinical practice.
Conflict of Interest: Authors declared no conflict of interest.

Financial Disclosure: There was no financial interest related to the material in the manuscript.

References

1. Beer R, Pfausler B, Schmutzhard E. Infectious intracranial complications in the neuro-ICU patient population. Curr Opin Crit Care. 2010;16(2):187–22. doi: 10.1097/MCC.0b013e328338cb5f. [PubMed: 20345521].

2. Dashni SR, Baharvahdat H, Spetzler RF, Sauvageau E, Chang SW, Stiebel MF, et al. Operative intracranial infection following craniotomy. Neurosurg Focus. 2008;24(6):10. doi: 10.3171/FOC/2008/24/E10. [PubMed: 18518740].

3. Jimenez CM, Polo J, Espana JA. Risk factors for intracranial infection secondary to penetrating craniocerebral gunshot wounds in civilian practice. World Neurosurg. 2013;79(5-6):749–55. doi: 10.1016/j.wneu.2012.06.025. [PubMed: 22722035].

4. Yu Y, Li HJ. Diagnostic and prognostic value of procalcitonin for early intracranial infection after craniotomy. Braz J Med Biol Res. 2017;50(5):6021. doi: 10.1590/1414-431X20176021. [PubMed: 28443989].

5. Lin C, Zhao X, Sun H. Analysis on the risk factors of intracranial complications in the neuro-ICU patient population. Curr Opin Crit Care. 2015;22(2):81–3. doi: 10.1097/MCC.0b013e32834101. [PubMed: 26512984].

6. Sturges BK, Dickinson PJ, Kortz GD, Berry WL, Vernau KM, Wisner ER, et al. Clinical signs, magnetic resonance imaging features, and outcome after surgical and medical treatment of otogenic intracranial infection in 4 dogs. Vet Intern Med. 2006;20(3):648–56. [PubMed: 16734101].

7. Chen K, Wu Y, Wang G, Wang J, Li X, Zhao Z, et al. The methodology and pharmacokinetics study of intraventricular administration of vancomycin in patients with intracranial infections after craniotomy. J Crit Care. 2015;30(1):218 et-5. doi: 10.1016/j.jcrc.2014.09.020. [PubMed: 25448880].

8. Fang YQ, Zhan RC, Jia W, Zhang BQ, Wang JJ. A case report of intraventricular tigecycline therapy for intracranial infection with extremely drug resistant Acinetobacter baumannii. Medicine (Baltimore). 2017;96(31):7703. doi: 10.1097/MD.0000000000007703. [PubMed: 28767065].

9. Tong SY, Davis JS, Eichenberger E, Holland TL, Fowler VI. Staphylococcus aureus aures infections: epidemiology, pathophysiology, clinical manifestations, and management. Clin Microbiol Rev. 2015;28(3):563-61. doi: 10.1128/CMR.00134-14. [PubMed: 26084341].

10. Roca I, Akova M, Rodriguez F, Carlet J, Cavalet M, Coenen S, et al. The global threat of antimicrobial resistance: science for intervention. New Microbes New Infect. 2015;6:22–9. doi: 10.1016/j.nmni.2015.02.007. [PubMed: 26029175].

11. van de Beek D, Drake JM, Tunkel AR. Nosocomial bacterial meningitis. N Engl J Med. 2010;362(2):144–54. doi: 10.1056/NEJMA0804573. [PubMed: 20097704].

12. Davis KA, Stewart JI, Crouch HK, Florez CE, Hosphenthal DR. Methicillin-resistant Staphylococcus aureus (MRSA) nares colonization at hospital admission and its effect on subsequent MRSA infection. Clin Infect Dis. 2004;39(6):776–82. doi: 10.1086/422997. [PubMed: 15472807].

13. Ruan L, Wu D, Li X, Huang Q, Lin L, Lin J, et al. Analysis of microbial community composition and diversity in postoperative intracranial infection using highthroughput sequencing. Mol Med Rep. 2017;16(4):3938–46. doi: 10.3892/mmr.2017.7082. [PubMed: 29067445].

14. Mashiko R, Taguchi S, Tobita T, Shibata Y. Intracranial infection caused by minor skin contusion associated with previous craniootomy. AMJ Case Rep. 2017;2017. doi: 10.1136/amerjcaserep-2016-217833. [PubMed: 28082307].

15. Wei ZQ, Shen P, Chen YB, Xiao Y, Lan-Xian Li, Mohnarin report of 2011: distribution and drug resistance of the bacteria causing blood stream infections. Chinese J Nosocomiol. 2012;22(24):549–502.

16. Kumar A, Randhawa VS, Nirupam N, Rai Y, Salli A. Risk factors for carbapenem-resistant Acinetobacter baumannii blood stream infections in a neonatal intensive care unit, Delhi, India. J Infect Dev Ctries. 2013;7(3):1049–54. doi: 10.3855/jidc.4242. [PubMed: 23166737].

17. Grundmann H, Livermore DM, Giske CG, Canton R, Rossolini GM, Campos J, et al. Carbapenem-non-susceptible Enterobacteriaceae in Europe: conclusions from a meeting of national experts. Euro Surveill. 2010;15(48). [PubMed: 2142021].

18. Kourbeti IS, Vakis AF, Ziakas P, Karabetsos D, Potolidis E, Christou S, et al. Infections in patients undergoing craniotomy: risk factors associated with post-craniotomy meningitis. J Neurosurg. 2015;122(5):621-9. doi: 10.3171/2014.8.JNS132557. [PubMed: 25343257].

19. Vossler AT, Kouris AP. Treatment of meningitis caused by methicillin-resistant Staphylococcus aureus with linezolid. Infection. 2007;35(4):271–4. doi: 10.1007/s00137-006-0421-z. [PubMed: 17649691].

20. Lee DH, Palermo B, Chowdhury M. Successful treatment of methicillin-resistant staphylococcus aureus meningitis with daptomycin. Clin Infect Dis. 2008;47(4):588–90. doi: 10.1086/590257. [PubMed: 18636684].

21. Florescu I, Beuran M, Dimov R, Razbadauskas A, Boczan M, Fichev G, et al. Efficacy and safety of tigecycline compared with vancomycin or linezolid for treatment of serious infections with methicillin-resistant Staphylococcus aureus or vancomycin-resistant enterococci: a Phase 3, multicentre, double-blind, randomized study. J Antimicrob Chemother. 2008;62 Suppl 1:i7–28. doi: 10.1093/jac/dkn250. [PubMed: 18684703].

Jundishapur J Microbiol. In Press(In Press):e60788.